Skip to main content

SARS-CoV-2-induced activation of pathogenic endogenous retrovirus envelope HERV-W: towards personalized treatment of COVID-19 patients

Objective

Severe COVID-19 disease and the high frequency of its long-term complications are now a major health problem worldwide. Due to the significant heterogeneity of COVID-19 disease profiles, biomarkers that allow either the identification of patients at high risk for developing severe forms of COVID-19 and its long-term complications, or guide personalized treatment options, are scarce. The HERVCOV project aims to analyze the role of human endogenous retroviruses (HERVs), known for their high pro-inflammatory potential, in the immunopathogenesis of COVID-19 and to identify and evaluate a set of biomarkers which will be important for the diagnosis, prognosis and follow-up of COVID-19 patients and their prioritization for targeted therapy. Recent data from the consortium has demonstrated that HERV-W envelope protein is highly expressed in lymphocytes of COVID-19 patients and correlates with inflammatory markers and respiratory outcome of the disease, strongly suggesting the role of HERVs in COVID-19 pathogenesis. The project aims to assess the biological pathways and functions that underlie the association of HERV expression and activation with severe COVID-19 forms and related complications. Biomarkers based on HERV pathogenic protein activation, SARS-CoV-2-specific immune responses, cytokine production and mandatory medical blood analyses for COVID-19 clinical monitoring will be studied in samples from different forms of COVID-19: acute, post- neuro- and long-COVID patients. Parameters will be determined that predict the clinical course of the disease and aggravation of SARS-CoV-2-induced symptoms and allow potential clustering of different bio-clinical profiles of COVID-19 patients. Diagnostic and prognostic panel(s) ?translated? from our fundamental research and subsequent evaluations of HERV-associated biomarkers will be assessed to define novel indicators in precision medicine-based therapeutic strategies, leading to individualized medical treatment in COVID-19.

Coordinator

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Net EU contribution
€ 2 224 387,00
Address
Rue De Tolbiac 101
75654 Paris
France

See on map

Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Non-EU contribution
€ 0,00

Participants (8)

ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON
Greece
Net EU contribution
€ 749 375,00
Address
6 Christou Lada Str
10561 Athina

See on map

Region
Κεντρικός Τομέας Αθηνών Aττική Αττική
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00
UNIVERSITA DEGLI STUDI DI ROMA TOR VERGATA
Italy
Net EU contribution
€ 850 268,00
Address
Via Cracovia 50
00133 Roma

See on map

Region
Centro (IT) Lazio Roma
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00
INSTITUTO ARAGONES DE CIENCIAS DE LA SALUD
Spain
Net EU contribution
€ 936 291,00
Address
Avenida San Juan Bosco 13
50009 Zaragoza

See on map

Region
Noreste Aragón Zaragoza
Activity type
Research Organisations
Non-EU contribution
€ 0,00
Third-party

Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.

FUNDACION AGENCIA ARAGONESA PARA LA INVESTIGACION Y EL DESARROLLO
Spain
Net EU contribution
€ 165 000,00
Address
Paseo Maria Agustin 36 Edificio Pignatelli Pta 30 Pl 2
50004 Zaragoza

See on map

Region
Noreste Aragón Zaragoza
Activity type
Other
Non-EU contribution
€ 0,00
GENEURO INNOVATION SAS
France
Net EU contribution
€ 633 296,00
Address
Avenue Rockefeller 60 Lyon Bioparc
69008 Lyon

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Auvergne-Rhône-Alpes Rhône-Alpes Rhône
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00
INSERM TRANSFERT SA
France
Net EU contribution
€ 356 500,00
Address
Rue Watt 7
75013 Paris

See on map

Region
Ile-de-France Ile-de-France Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00
ASSOCIAZIONE FRASCATI SCIENZA
Italy
Net EU contribution
€ 533 750,00
Non-EU contribution
€ 0,00
KLINICKI BOLNICKI CENTAR RIJEKA
Croatia
Net EU contribution
€ 397 290,00
Address
Kresimirova 42
51000 Rijeka

See on map

Region
Hrvatska Jadranska Hrvatska Primorsko-goranska županija
Activity type
Research Organisations
Non-EU contribution
€ 0,00